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In	 this	 thesis	we	primarily	 looked	at	 2	 cohort	of	 patients	A)	Myocardial	 infarction	
with	non-obstructed	coronaries(MINOCA)	group	(388	subjects)	and	B)	ST	segment	




MINOCA	 study	 -	 In	 a	 large	 cohort	 of	 MINOCA,	 CMR	 (median	 37days	 from	














In	 STEMI	 –	 Via	 non-invasive	 advanced	 CMR	 relaxometry	 technique	 the	 study	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































while in suspected anomalous coronary arteries and
myocardial bridging a chronotropic and inotropic
agent (dobutamine) is more appropriate.
Recent technical developments in accelerating
imaging acquisition15 and the introduction of 3 T
(higher magnetic field strength) has improved the
diagnostic accuracy of CMR stress imaging (better
visualisation of small perfusion defects), capitalising
on higher field homogeneity and higher perform-
ance gradients than at 1.5 T.16 However, the field
homogeneity is more complex to achieve at 3 T vs
1.5 T and any remaining inhomogeneity does affect
image quality.
Late gadolinium enhancement imaging
This T1-weighted technique is the cornerstone
of myocardial tissue characterisation. It can
demonstrate the presence and extent of myocardial
scarring.
In brief, the gadolinium-chelate contrast agent
administered intravenously promptly diffuses into
the extracellular myocardial compartment. In
normal myocardium, the contrast quickly washes in
and out of the myocardium. The presence of myo-
cardial scarring results in increased extracellular
space, where the contrast accumulates with longer
washout time compared to normal myocardium
(figure 2). The accumulation and distribution of
the contrast agent in the diseased myocardium
follows the pathophysiological process of the
underlying condition. In IHD, the myocardial
ischaemic-necrotic wave-front phenomenon starts
in the subendocardium, becoming progressively
more transmural with ischaemic time. Therefore, in
Figure 1 Top panel shows the four-chamber and two-chamber cines. Lower panel (1–9) short-axis cine dataset covering the heart, obtained by
cutting the heart from base to apex.














































IHD the LGE pattern can be either subendocardial
or transmural, with the infarcted myocardium
appearing as a hyperintense (bright) area (accumu-
lation of contrast) and the normal myocardium as a
hypointense area (no accumulation of contrast).
LGE volume changes, in the minutes following
contrast administration in acute but not in chronic
myocardial infarction (MI). In acute infarct trans-
murality 25 min postcontrast injection better pre-
dicts infarct size and functional recovery.17
In the setting of acute MI, LGE imaging can also
detect areas of hypointensity within the bright
infarcted area, representing areas of microvascular
obstruction (MVO), precluding entry of gadolinium
into these areas.
In patients with IHD, a standard CMR imaging
protocol includes both cine and LGE imaging;
myocardial oedema can be added in the acute
setting to confirm the presence/absence of STIR. In
addition, stress/rest first-pass perfusion can help to
delineate the presence of inducible myocardial
ischaemia (table 1). A typical CMR scan duration is
∼45 min (figures 3 and 4).
Native T1 and extracellular volume fraction
quantification (ECV)
Both native T1 and extracellular volume fraction
quantification (ECV) are new technical developments
offering an unprecedented opportunity to quantify
changes in myocardial intracellular and extracellular
compartments in a non-invasive manner, bringing a
new dimension to myocardial tissue characterisation
beyond conventional LGE imaging.
While alteration in native T1 may result from
processes affecting the intracellular and/or extracel-
lular compartments of the myocardium, ECV spe-
cifically quantifies expansion of the interstitial
space. Currently, these sequences are mainly used
for research, but their use for improved diagnosis
and prognostication is promising.18
B) THE CMR CLINICAL REPORT
Images acquired by CMR need to be interpreted in
the appropriate clinical context. Clinical informa-
tion, including ECG, echocardiography, coronary
angiography and cardiac biomarkers, is desirable
to be able to tailor image acquisition based on the
clinical question, and to allow a more accurate
interpretation of the findings. A typical CMR
report includes a description of the findings, fol-
lowed by the clinical interpretation of the findings.
Figure 5 illustrates a step-by-step approach on the
Figure 2 Gadolinium kinetics in normal myocardium and acute and chronic myocardial infarction. (A) Normal myocardium with an intact cell
membrane. Gadolinium washes in and then promptly washes out of normal myocardium. (B) Acute myocardial infarction with ruptured cell
membrane. Gadolinium washes out of acutely infarcted myocardium less quickly than normal due to an expanded volume of distribution as a result
of disruption to the cell membrane. (C) Chronic myocardial infarction with collagen matrix scar formation. Gadolinium washes out of chronic
myocardial infarction less quickly than normal due to increased interstitial space within the collage matrix scar. K+=potassium ion; Na+=sodium
ion; Gd, gadolinium. Adapted from Kim et al.110
Table 1 CMR protocol for ischaemic heart disease107
Clinical application
(A) Acute MI or acute coronary syndromes
1. Cines (short and long axis) LV function
Ischaemia/viability (during dobutamine)
2. Advanced tissue characterisation sequences
(eg, T2 weighted imaging, T1 mapping)
Myocardial oedema
3. Optional—first pass perfusion at rest
Consider stress in bystander disease assessment
MVO
Ischaemia
4. Early gadolinium enhancement MVO
Thrombus
5. Late gadolinium enhancement Viability
Infarct size
(B) Chronic ischaemic heart disease
1. Cines (short and long axis) LV structure and function
Ischaemia/viability (dobutamine)
2. Optional—low-dose dobutamine with 5–10 min
infusion of 10 μg/kg/min of dobutamine
Assess contractile reserve (improvement in wall
thickening)
3. Optional—adenosine stress–rest perfusion or
high-dose dobutamine functional imaging
Inducible ischaemia
4. Early gadolinium enhancement Thrombus
6. Late gadolinium enhancement Viability
Infarct size
CMR, cardiac MRI; LV, left ventricle; MI, myocardial infarction; MVO, microvascular obstruction.













































analysis and interpretation of a typical CMR
report.
C) COMPARISON WITH OTHER IMAGING
MODALITIES
In the assessment of IHD, clinicians are often
posed with the dilemma of which non-invasive car-
diovascular imaging modality to choose. CMR is
superior to several other functional imaging
modalities, especially in certain circumstances, like
in obese subjects, in females, in acute myocardial
injury and in the assessment of myocardial viabil-
ity. Table 2 summarises the relative merits and
demerits of the different functional imaging
modalities available, highlighting the superiority of
CMR.19 20
Figure 3 A case of acute ST elevation myocardial infarction with culprit diagonal coronary artery. The short axis cines showing the wall motion
abnormality, T2 short-τ inversion recovery (STIR) imaging showing myocardial oedema or area at risk (arrow), rest perfusion showing early
microvascular obstruction (arrow) and late gadolinium imaging showing lateral wall transmural enhancement with microvascular obstruction (arrow).
Figure 4 Assessment of chronic ischaemic heart disease: A patient with previous anterior myocardial infarction assessed for ischaemic heart
disease. Stress perfusion imaging showed basal inferior perfusion defect (arrow), and late enhancement imaging showed transmural myocardial
infarction in the mid-distal left anterior descending territory with viable inferior wall.









IHD the LGE pattern can be either subendocardial
or transmural, with the infarcted myocardium
appearing as a hyperintense (bright) area (accumu-
lation of contrast) and the normal myocardium as a
hypointense area (no accumulation of contrast).
LGE volume changes, in the minutes following
contrast administration in acute but not in chronic
myocardial infarction (MI). In acute infarct trans-
murality 25 min postcontrast injection better pre-
dicts infarct size and functional recovery.17
In the setting of acute MI, LGE imaging can also
detect areas of hypointensity within the bright
infarcted area, representing areas of microvascular
obstruction (MVO), precluding entry of gadolinium
into these areas.
In patients with IHD, a standard CMR imaging
protocol includes both cine and LGE imaging;
myocardial oedema can be added in the acute
setting to confirm the presence/absence of STIR. In
addition, stress/rest first-pass perfusion can help to
delineate the presence of inducible myocardial
ischaemia (table 1). A typical CMR scan duration is
∼45 min (figures 3 and 4).
Native T1 and extracellular volume fraction
quantification (ECV)
Both native T1 and extracellular volume fraction
quantification (ECV) are new technical developments
offering an unprecedented opportunity to quantify
changes in myocardial intracellular and extracellular
compartments in a non-invasive manner, bringing a
new dimension to myocardial tissue characterisation
beyond conventional LGE imaging.
While alteration in native T1 may result from
processes affecting the intracellular and/or extracel-
lular compartments of the myocardium, ECV spe-
cifically quantifies expansion of the interstitial
space. Currently, these sequences are mainly used
for research, but their use for improved diagnosis
and prognostication is promising.18
B) THE CMR CLINICAL REPORT
Images acquired by CMR need to be interpreted in
the appropriate clinical context. Clinical informa-
tion, including ECG, echocardiography, coronary
angiography and cardiac biomarkers, is desirable
to be able to tailor image acquisition based on the
clinical question, and to allow a more accurate
interpretation of the findings. A typical CMR
report includes a description of the findings, fol-
lowed by the clinical interpretation of the findings.
Figure 5 illustrates a step-by-step approach on the
Figure 2 Gadolinium kinetics in normal myocardium and acute and chronic myocardial infarction. (A) Normal myocardium with an intact cell
membrane. Gadolinium washes in and then promptly washes out of normal myocardium. (B) Acute myocardial infarction with ruptured cell
membrane. Gadolinium washes out of acutely infarcted myocardium less quickly than normal due to an expanded volume of distribution as a result
of disruption to the cell membrane. (C) Chronic myocardial infarction with collagen matrix scar formation. Gadolinium washes out of chronic
myocardial infarction less quickly than normal due to increased interstitial space within the collage matrix scar. K+=potassium ion; Na+=sodium
ion; Gd, gadolinium. Adapted from Kim et al.110
Table 1 CMR protocol for ischaemic heart disease107
Clinical application
(A) Acute MI or acute coronary syndromes
1. Cines (short and long axis) LV function
Ischaemia/viability (during dobutamine)
2. Advanced tissue characterisation sequences
(eg, T2 weighted imaging, T1 mapping)
Myocardial oedema
3. Optional—first pass perfusion at rest
Consider stress in bystander disease assessment
MVO
Ischaemia
4. Early gadolinium enhancement MVO
Thrombus
5. Late gadolinium enhancement Viability
Infarct size
(B) Chronic ischaemic heart disease
1. Cines (short and long axis) LV structure and function
Ischaemia/viability (dobutamine)
2. Optional—low-dose dobutamine with 5–10 min
infusion of 10 μg/kg/min of dobutamine
Assess contractile reserve (improvement in wall
thickening)
3. Optional—adenosine stress–rest perfusion or
high-dose dobutamine functional imaging
Inducible ischaemia
4. Early gadolinium enhancement Thrombus
6. Late gadolinium enhancement Viability
Infarct size
CMR, cardiac MRI; LV, left ventricle; MI, myocardial infarction; MVO, microvascular obstruction.










Transmurality is associated with worse outcome,
and CMR-derived acute infarct size is a stronger
predictor of future events.37 Several methods exist
to quantify transmurality, including semi-automated
techniques (mainly used in research).38 In
reperfused STEMI patients time to reperfusion
determines the extent of reversible and irreversible
myocardial injury as assessed by CMR. Particularly,
salvaged myocardium is markedly reduced when
reperfusion occurs >90 min of coronary
occlusion.39
Both CMR-derived infarct size and myocardial
salvage have prognostic importance.40 41 Myocardial
oedema is maximal and constant over the first week
post MI, thereby providing a window for the retro-
spective evaluation of AAR whereas LGE recedes
over time with corresponding recovery of function,
indicating that acutely detected LGE does not neces-
sarily equate with irreversible injury and may severely
underestimate salvaged myocardium.42
CMR is not routinely performed in STEMI
patients. However, it provides an opportunity to
further understand the degree of LV dysfunction
and underlying myocardial damage.
Microvascular obstruction
This is a feature of acute myocardial damage,
encountered in up to 30% of patients with
STEMI.43 The presence and extent of MVO after
acute MI is associated with adverse LV remodelling
and poor clinical outcome,44–46 and myocardial
segments exhibiting MVO are more likely to
develop wall thinning and not regain function.47
MVO is a powerful predictor of global and regional
functional recovery than the transmurality.48
CMR-derived infarct size and MVO provide inde-
pendent and incremental prognostic information in
addition to clinical risk scores and LV ejection frac-
tion.49 In another study, MVO was an independent
predictor of major adverse cardiac events (MACE)
and cardiac death, whereas infarct size was not.50
De Waha et al51 showed that the ratio of MVO/
infarct size is a more powerful predictor for long-
term outcome than either parameter alone.
Intramyocardial haemorrhage
Intramyocardial haemorrhage (IMH) is another
sequelae of microvascular damage, appearing as
hypointense areas in the rest first-pass perfusion
and LGE images, similarly to MVO. The distinctive
aspect of IMH compared with MVO is the hypoin-
tense signal also in the T2-weighted images caused
by the haemoglobin breakdown products, not
observed in MVO. Therefore, T2-weighted images
are essential for distinguishing IMH from MVO.
Infarct size, myocardial salvage, MVO and IMH
measured by CMR are increasingly used as surro-
gate endpoints in clinical trials of acute MI and
reperfusion strategies.52 For example, the EXPIRA
trial showed that in STEMI, thrombectomy pre-
vents thrombus embolisation and improves micro-
vascular integrity by reducing the presence and
extent of MVO and infarct size measured by
CMR.53 Another study showed that IMH can
predict MACE and adverse remodelling; however
the study failed to show an improvement in the
predictive value of LGE-CMR by adding T2
imaging.54
Table 2 Comparison of different functional imaging
modalities in the assessment of IHD (CMR vs Echo vs
SPECT)
CMR Echo SPECT
Ejection fraction +++ ++ +
RWMA +++ ++ −
Wall thinning ++ + −
Myocardial oedema ++ − −
Viability +++ ++ +++
MVO +++ − −
Thrombus ++ + −
Valve assessment + +++ −
RV +++ ++ +
Ischaemia assessment
Increased BMI ++ + ++
Female ++ ++ +
Adenosine ++ + ++
Dobutamine ++ ++ ++
Exercise (+) +++ ++
BMI, body mass index; CMR, cardiac MRI; IHD, ischaemic heart
disease; MVO, microvascular obstruction; RV, right ventricle;
RWMA, regional wall motion abnormality; SPECT, single-photon
emission computed tomography.
Box 1 Recent European Society of Cardiology (ESC) guidelines:
Indications for use of cardiac MRI (CMR) in ischaemic heart disease
(IHD)21 98 108
In Non ST-Elevation—acute coronary syndrome (ESC Guideline 2011)21
In patients without recurrence of pain, normal echocardiography (ECG)
findings, negative troponins tests, and a low-risk score, a non-invasive stress
test for inducible ischaemia is recommended before deciding on an invasive
strategy
CMR imaging is useful to assess myocardial viability and to detect myocarditis
In ST-Elevation Myocardial Infarction (STEMI) (ESC Guideline 2012)108
CMR may be used as an alternative for assessment of infarct size and resting
left ventricular (LV) function, if echocardiography is not feasible, after STEMI
For patients with multivessel disease, or in whom revascularisation of other
vessels is considered, stress imaging to demonstrate ischaemia and viability is
an option
In stable coronary artery disease (chronic ischaemic heart disease)98
Basic testing: CMR is recommended to evaluate ventricular function and define
structural cardiac abnormalities when transthoracic echocardiogram is
suboptimal
Diagnosing ischaemia: Perfusion CMR or dobutamine stress CMR has good
diagnostic accuracy
Risk stratification: LV function is the strongest predictor of long-term survival.
In addition, new wall motion abnormalities (≥3 segments in the 17 segment
model) induced by stress or stress-induced reversible perfusion deficits >10%
(≥2 segments) of the LV myocardium regarded as high risk
Assess coronary anatomy: MR coronary angiography can delineate coronary
anatomy. It is used for research purpose and is not recommended for
diagnostic evaluation of stable CAD.











assessment,87 demonstrating that LGE provided the
highest sensitivity (95%) and negative predictive
value (90%), whereas low-dose dobutamine offered
the best specificity (91%) and positive predictive
value (93%). A combination of viability parameters
(transmurality, contractile reserve, EDWT, unen-
hanced rim thickness and segmental wall thickening
of the unenhanced rim) may be a better predictor
of recovery.88
Inducible myocardial ischaemia
The FAME study89 established that revascularisa-
tion of patients with symptomatic stable CAD
guided by the presence of myocardial ischaemia
measured invasively by fractional flow reserve
(FFR) is prognostically important. Furthermore, a
meta-analysis demonstrated that the absence of
ischaemia confers prognostic benefit, with very low
annualised event rates for cardiovascular death
(0.3%) and MI (0.4%).90 The ongoing
MR-INFORM study is assessing whether a CMR
stress perfusion strategy is non-inferior to FFR in
stable CAD.91 The ongoing ISCHEMIA trial will
demonstrate whether patients with moderate–
Table 3 CMR findings in assessment of IHD and its impact on clinical
management
Impact on clinical management* Prognostic
LV EF Guide heart failure therapy
CRT/ICD implantation
Yes
RWMA Assessment of hibernation No
LGE Distinguish ischaemic from non-IHD
Assessment of viability (Guide revascularisation)
Help in LV lead implantation (presence of transmural
posterolateral LGE—poor responder)
Yes
Ischaemia Diagnosis of IHD as the cause of chest pain
Guide revascularisation
Yes
MVO Predictive of poor clinical outcome (adverse remodelling)
Extended hospital stay and close follow-up after discharge
Yes
Thrombus Delineate the character and location
Initiation of anticoagulation therapy
No
Myocardial oedema Differentiate acute from chronic
Assessment of area at risk and salvaged myocardium
Yes
RV function Guide in appropriate right heart failure management Yes
*Further details consult the European Society of Cardiology (ESC), AHA or National Institute for Health
and Care Excellence (NICE) guidelines on ischaemic heart disease.
CMR; cardiac MRI; CRT, cardiac resynchronisation therapy; ICD, implantable cardioverter-defibrillator;
IHD, ischaemic heart disease; LGE, late gadolinium enhancement; LV EF, left ventricular ejection
fraction; MVO, microvascular obstruction; RV, right ventricle, RWMA, regional wall motion
abnormality.
Table 4 Contraindications of CMR
Absolute contraindication Relative contraindication
MRI ▸ Intracranial aneurysm clips ▸ Clinically unstable patients
▸ Automated implantable cardiac defibrillator (ICD) ▸ Long-stem joint prosthesis (at 3 T only)
▸ Non-MR conditional pacemaker ▸ Severe claustrophobia
▸ Pacing dependent patient
▸ Cochlear, otological or ear implant
▸ Metallic intraocular foreign body
▸ Neurostimulator
▸ Non-MR conditional monitoring devices
▸ Non-MR conditional support devices
Gadolinium-chelate contrast agent ▸ Previous anaphylactic reaction to gadolinium contrast ▸ Renal impairment (eGFR <30 mL/min/1.73 m2)
▸ Known nephrogenic systemic fibrosis (NSF) ▸ Hepatorenal syndrome
▸ Pregnancy
Adenosine ▸ Previous anaphylactic reaction to adenosine ▸ Mild-moderate obstructive airways disease
▸ Previous anaphylactic reaction to regadenoson ▸ Caffeine <6–12 h
▸ Acute coronary or aortic syndrome ▸ Concomitant theophylline
▸ High degree atrioventricular block ▸ Concomitant dipyridamole
▸ Severe obstructive airways disease ▸ Aberrant conduction/pre-excitation
▸ Symptomatic severe or critical aortic stenosis
▸ Systolic blood pressure < 90 mm Hg
▸ Bradycardia (heart rate <40 beats per minute)
Dobutamine ▸ Previous anaphylactic reaction to dobutamine ▸ Hypokalaemia
▸ Acute coronary or aortic syndrome ▸ Left ventricular thrombus
▸ Symptomatic severe or critical aortic stenosis ▸ Intracranial aneurysm
▸ Obstructive hypertrophic cardiomyopathy ▸ Abdominal aortic aneurysm
▸ High degree atrioventricular block ▸ Severe ventricular arrhythmias
▸ Uncontrolled arterial hypertension
▸ Uncontrolled atrial fibrillation
Atropine ▸ Acute-angle glaucoma ▸ Obstructive uropathy
▸ Myasthenia gravis
▸ Pyloric stenosis
CMR, cardiac MRI; eGFR, estimated glomerular filtration rate; ICD, implantable cardiac defibrillator; NSF nephrogenic systemic fibrosis.






































































































































(n=204)	 (n=98)	 (n=106)	 (n=58)	 (n=58)	
Mean	age	(SD)	 56	(17)	 56(18)	 57(17)	 0.71	 56(17)	 53(17)	 0.43	
Male	sex	%	 51	 54	 48	 0.4	 53	 50	 0.85	
Family	history	of	
IHD	%	
3	 3	 4	 1	 5	 5	 1	
Diabetes	%	 6	 4	 9	 0.25	 5	 9	 0.72	
Hypertension	%	 17	 12	 22	 0.09	 14	 17	 0.8	
History	of	smoking	%	 7	 6	 8	 0.78	 7	 7	 1	
LV	function	Echo	%	
	 	 	 	 	 	 	
Normal	 62	 53	 71	 0.009	 60	 73	 0.23	
Mild	 20	 20	 19	 0.86	 15	 15	 1	
Moderate	 12	 17	 7	 0.05	 15	 7	 0.23	
Severe	 6	 9	 4	 0.15	 10	 5	 0.49	
Mean	troponin	T	ng/L	 640	 762	 477	 0.003	 708	 506	 0.13	
Presentation	as	
STEMI	%	




32	 5	 56	 <0.0001	 5	 55	 <0.0001	
Diagnosis	%	 70	 84	 57	 <0.0001	 88	 50	 <0.001	
































































































Myocardial	 damage	 and	 oedema	 associated	 with	 myocarditis	 (55)	 and	 transient	
apical	ballooning/Tako-Tsubo	cardiomyopathy	(61,164)	are	acute	processes	that	may	
have	 a	 poor	 prognosis.	 (33)(165)(81,82)	 CMR	 can	 delineate	 the	 severity	 of	
myocarditis	and	Tako-Tsubo	cardiomyopathy	thereby	guiding	management	and	risk	
stratification.	 LGE	 is	 the	 best	 independent	 predictor	 of	mortality	 in	 biopsy-proven	




appropriate	 therapy,	 including	 immunosuppressant,	 early	 referral	 for	 myocardial	
biopsy	or	help	in	MR	guided	biopsy.		Likewise,	Tako-Tsubo	cardiomyopathy	is	usually	
considered	 to	 be	 a	 benign	 reversible	 condition,	 however	 its	 arrhythmic	 risk	 is	
increasingly	 recognized.	There	are	promising	new	CMR	analyses	which	may	help	 in	
risk	 stratification.	 (81)	 Identification	 of	 a	 reversible	 cardiomyopathy	 may	 help	 to	
prevent	subsequent	unnecessary	invasive	procedure	(for	example	ICD	implantation).	
Moreover	 CMR	 can	 also	 help	 in	 diagnosis	 and	 risk	 stratification	 in	MI.	 CMR	 allow	
accurate	 assessment	 of	 infarct	 size	 (LGE),	 myocardial	 salvage	 and	 microvascular	
obstruction.	All	 these	high-risk	 features	can	only	be	delineated	 in	 the	acute	phase.	































































































































Propensity score matching identified 58 pairs
of early and late subjects. The results confirmed
the significantly higher diagnostic yield in the
propensity-matched early group versus late group
(88% vs. 50%; p < 0.0001). The clinical impact also
improved significantly in the propensity-matched
early CMR group (76% vs. 51%; p ¼ 0.01).
The study demonstrated the importance of per-
forming CMR early in MINOCA, which provides a
window of opportunity to image myocardial damage
before healing occurs, thereby maximizing the diag-
nostic yield. This is particularly relevant in poten-
tially reversible conditions (acute myocarditis and
Takotsubo cardiomyopathy).
The timing of CMR was partly based on the
referring physician’s discretion or scanner availabil-
ity. However, with propensity scoring, we matched
the early CMR group with the late CMR group,
thereby reducing the selection bias. CMR-guided
diagnosis was assumed to be correct based on
previous literature (2).
In conclusion, in consecutive patients with
MINOCA, CMR established a definitive diagnosis in
70% of patients and made a significant additive
impact on diagnosis and/or clinical management in
66% of patients, with LGE being the best independent
predictor of clinical impact more than the traditional
clinical and diagnostic markers. Moreover, the diag-
nostic value and the clinical impact of CMR were
highest when performed within 2 weeks from
presentation.
Amardeep Ghosh Dastidar, MBBS(Hons)
Jonathan C.L. Rodrigues, BSc(Hons), MBChB(Hons)






































































(A) Comparison of pre-cardiac magnetic resonance (CMR) with post-CMR diagnosis. Green cells denote changes in diagnosis, pink cells show
an agreement between pre- and post-CMR, and white cells show if the CMR showed a structurally normal heart. Uncertain was defined when
the referring clinician had $2 differential pre-CMR diagnoses. (B) Overall clinical impact (n ¼ 204). White cells denote no change, green cells
show if there was a new diagnosis or a change in management, and pink cells show if both were present. CM ¼ cardiomyopathy;
MI ¼ myocardial infarction; MINOCA ¼ myocardial infarction with nonobstructed coronary arteries.
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			Lower	 			Upper	 			Lower	 			Upper	
Age	 0.008	 1.024	 1.006	 1.041	 0.002	 1.035	 1.013	 1.058	
Sex	 0.77	 1.091	 0.609	 1.954	 0.604	 0.831	 0.413	 1.673	
Troponin		 0.209	 1	 1	 1.001	 0.474	 1	 1	 1.001	
STEMI	 0.224	 1.63	 0.742	 3.577	 0.966	 0.981	 0.412	 2.338	
iEDV	 0.291	 1.006	 0.995	 1.017	 0.316	 1.006	 0.994	 1.019	
LVEF	 0.597	 0.995	 0.975	 1.015	 0.847	 1.002	 0.98	 1.025	
RWMA	 0.121	 1.616	 0.881	 2.966	 0.959	 1.02	 0.475	 2.192	
Oedema	 0.078	 1.765	 0.938	 3.323	 0.527	 1.298	 0.579	 2.912	




























































Acute	 coronary	 syndrome	 (ACS)	 is	 one	 of	 the	 leading	 causes	 of	 mortality	 and	
morbidity	 worldwide.(152)	 Definite	 diagnosis	 of	 ACS	 is	 crucial	 for	 ensuring	
appropriate	 patient	 management.	 As	 per	 the	 international	 guidelines,	 patients	
presenting	 with	 ST-segment	 elevation	 myocardial	 infarction	 (STEMI)	 or	 non-ST-
segment	 elevation-acute	 coronary	 syndrome	 (NSTE-ACS)	 proceed	 to	 immediate	 or	
inpatient	 coronary	 angiography,	 respectively,	 with	 the	 aim	 to	 identify	 and	 treat	 a	
culprit	 coronary	 artery	 occlusion	 or	 stenosis.(5,8)	 However,	 in	 7-15%	 of	 these	
patients	 no	 significant	 coronary	 obstruction	 is	 identified,	 thus	 being	 classified	 as	
MINOCA	(Myocardial	infarction	with	non-obstructive	coronary	arteries).(8)	MINOCA	
represents	a	diagnostic	dilemma,	with	subsequent	uncertain	clinical	management.	A	
recent	 registry	 study	 has	 shown	 beneficial	 effects	 of	 treatment	 with	 statins	 and	
angiotensin-converting	enzyme	inhibitors/angiotensin	receptor	blockers	on	outcome	
in	patients	with	MINOCA.(167)	
The	 underlying	 pathophysiological	 mechanisms	 occurring	 in	 MINOCA	 are	 complex	
and	multifactorial.	 A	 recent	 review	 article	 by	Niccoli	 et	 al.	 described	 the	 potential	
mechanisms	 and	 proposed	 a	management	 algorithm	 for	 this	 cohort.(153)	 Patients	
with	 MINOCA	 are	 thought	 to	 have	 a	 better	 prognosis,	 and	 consequently	 do	 not	
receive	appropriate	secondary	prevention	medications.(22)	However,	recent	studies	
suggest	 that	 all-cause	mortality	may	 be	 as	 high	 as	 4.7%	 at	 12	months.(21,28)	 The	
latest	ESC	guidelines	on	the	management	of	STEMI	has	included	MINOCA	suggesting	
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a	 potential	 role	 for	 cardiovascular	 magnetic	 resonance	 (CMR)	 in	 this	 cohort.(8)	
Confirmation	or	exclusion	of	myocardial	infarction	(MI)	by	(CMR)	facilitates	tailoring	
of	 medical	 therapy,	 ensuring	 appropriate	 long-term	 secondary	 prevention	 and	
modification	 of	 risk	 but	 also	minimizing	 exposure	 to	 anti-platelet	 therapy	 and	 the	
associated	 bleeding	 risks	 for	 those	with	 a	 non-coronary	 aetiology	 for	 the	MINOCA	
presentation.(160)	 CMR	 also	 helps	 in	 reassuring	 the	 patient	 by	 having	 identified	 a	
clear	 cause	 of	 the	 episode	 that	 led	 to	 their	 admission	 to	 hospital.	 Few	 previous	
studies	have	shown	that	CMR	can	identify	the	underlying	diagnosis,	most	commonly:	
acute/chronic	 myocarditis,	 acute	 MI	 with	 spontaneous	 recanalization/embolus,	
stress	 cardiomyopathy	 (Takotsubo)	 or	 other	 cardiomyopathies.(29,30,32–34,36,37)	
Only	in	a	small	proportion	of	cases,	no	abnormality	is	identified	by	CMR.	The	variable	
proportion	 of	 normal	 cases	 in	 the	 different	 studies	may	 be	 due	 to	 the	 time	 delay	
between	the	acute	presentation	and	CMR,	 (168)	suggesting	that	 the	time	between	
acute	 presentation	 and	 CMR	 can	 play	 a	 role	 in	 identifying	 the	 early	 reversible	
abnormalities	that	may	resolve	when	patients	are	scanned	later.	Recent	studies	have	
demonstrated	 the	prognosis	 in	 the	 individual	diagnostic	categories	 like	myocarditis	
and	 Takotsubo	 cardiomyopathy.	 (169–171)	 However,	 there	 is	 no	 evidence	 in	 the	
literature	on	 the	prognostic	 significance	of	 the	CMR	 findings	and	 conventional	 risk	
factors	in	MINOCA.	The	only	study	which	looked	at	mid-term	mortality	was	by	Mittal	
et	 al.	 (172)	 However	 they	 looked	 at	 patients	 presenting	 via	 the	 primary	












or	 arrhythmic	 events	 at	 presentation.	 The	 study	 was	 performed	 at	 a	 large	
cardiothoracic	tertiary	centre	in	the	South-West	of	England;	data	were	collected	on	
consecutive	 patients	 scanned	 from	 September	 2011	 to	 December	 2015.	 Patients	
were	identified	either	presenting	with	STEMI	or	NSTEMI.		Non-obstructed	coronaries	
were	defined	as:	TIMI	 III	 flow;	<50%	stenosis	 in	any	coronary	artery.(8)	Troponin	T	
level	<14ng/L	was	considered	normal.	 ‘False	positive’	troponin	possibilities:	a	single	




A cute coronary syndrome (ACS) is oneof the leading causes of mortalityand morbidity worldwide (1). Defi-
nite diagnosis of ACS is crucial for ensuring
appropriate patient management. As per the
international guidelines, patients presenting
with ST-segment elevation myocardial
infarction (STEMI) or non-ST-segment eleva-
tion-ACS (NSTE-ACS) proceed to immediate
or inpatient coronary angiography, respec-
tively, with the aim to identify and treat a
culprit coronary artery occlusion or stenosis
(2,3). In 1% to 14% of these patients, howev-
er, no significant coronary obstruction is
identified, and thus these cases are classified
as myocardial infarction with nonobstructive
coronary arteries (MINOCA) (3). MINOCA rep-
resents a diagnostic dilemma, with subse-
quent uncertain clinical management. A
recent registry study has shown beneficial ef-
fects of treatment with statins and
angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers on outcome in
patients with MINOCA (4).
The underlying pathophysiological mech-
anisms occurring in MINOCA are complex
and multifactorial (5). Patients with MINOCA
are thought to have a better prognosis and conse-
quently do not receive appropriate secondary pre-
vention medications (6); however, recent studies
suggest that all-cause mortality may be as high as
4.7% at 12 months (7,8). The latest European Society
of Cardiology (ESC) guidelines on the management of
STEMI and the recent ESC/American College of Car-
diology/American Heart Association/World Heart
Federation fourth universal definition of myocardial
infarction has included MINOCA, suggesting a po-
tential role for cardiovascular magnetic resonance
(CMR) in this cohort (3,9).
Confirmation or exclusion of myocardial infarction
(MI) by CMR facilitates tailoring of medical therapy,
ensuring appropriate long-term secondary preven-
tion and modification of risk, and minimizing expo-
sure to antiplatelet therapy and the associated
bleeding risks for those with a noncoronary etiology
for the MINOCA presentation (10). Few previous
studies have shown that CMR can identify the un-
derlying diagnosis, which is made most commonly
based on acute/chronic myocarditis, acute MI with
spontaneous recanalization/embolus, stress cardio-
myopathy (Takotsubo), or other cardiomyopathies
(11–17). Only in a small proportion of cases is no ab-
normality identified by CMR. The variable proportion
of normal cases in the different studies may be due to
the time delay between the acute presentation and
CMR (18), suggesting that the time between acute
presentation and CMR can play a role in identifying
the early reversible abnormalities that may resolve
when patients are scanned later. Recent studies have
demonstrated the prognosis in the individual diag-
nostic categories such as myocarditis and Takotsubo
cardiomyopathy (19–21); however, there is no evi-
dence in the literature on the prognostic significance
of the CMR findings and conventional risk factors in
MINOCA. The only study that looked at midterm
mortality was by Mittal et al. (22); however, they
looked at patients presenting via the primary percu-
taneous coronary angiography pathway with non-
obstructed coronaries. Sixty percent of the study
population had normal troponin and thereby did not
strictly meet MINOCA criteria. Our study aimed to
assess the prognostic impact of CMR and conven-
tional risk factors in patients with MINOCA.
METHODS
STUDY POPULATION. In this longitudinal observa-
tional study, consecutive patients presenting with
MINOCA (chest pain, elevated troponin, and non-
obstructed coronary arteries) per the new ESC STEMI
Guideline (3) and undergoing CMR were identified
retrospectively and followed prospectively (Figure 1).
We excluded patients admitted with suspected heart
failure or arrhythmic events at presentation. The
study was performed at a large cardiothoracic tertiary
center in southwest England; data were collected on
FIGURE 1 Study Flow Chart
Emergency/urgent coronary angiography
n = 11,757
MINOCA referred for CMR
n = 410
Excluded
• Incomplete CMR protocol n = 8
• >50% stenosis n = 14
Study sample (n = 388)
ST segment elevation
n = 74
Non ST segment elevation
n = 314
CMR ¼ cardiovascular magnetic resonance; MINOCA ¼ myocardial infarction with non-
obstructed coronaries.
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
CMR = cardiac magnetic
resonance
ECG = electrocardiogram
iEDV = indexed end-diastolic
volume
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular ejection
fraction







RV = right ventricular
RWMA = regional wall motion
abnormality
STEMI = ST-segment elevation
myocardial infarction
STIR = short tau inversion
recovery
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4	 categories	 based	 on	 their	 CMR	 characteristics:	 myocardial	 infarction	 (MI)	
(embolic/spontaneous	 recanalization),	 myocarditis,	 cardiomyopathy	 and	 normal	
CMR.	The	latter	corresponded	to	a	structurally	normal	heart,	defined	as	no	regional	
wall	 motion	 abnormality	 (RWMA)	 (except	 for	 dyssynchrony	 secondary	 to	 bundle	
branch	block),	no	myocardial	oedema,	and	no	myocardial	LGE	(scarring)	(except	non-
specific	LGE	in	LV/RV	insertion	points).	Myocarditis	was	diagnosed	based	on	fulfilling	
two	 out	 of	 three	 Lake	 Louise	 Criteria:	 STIR	 T2-weighted	 sequences	 detecting	
myocardial	oedema;	early	gadolinium	sequences	detecting	hyperaemia;	epicardial	or	
mid-myocardial	 LGE,	 as	 previously	 described	 (55).	 MI	 was	 diagnosed	 based	 on	
territorial	 subendocardial	 and/or	 transmural	 LGE.	 Takotsubo	 cardiomyopathy	 was	
diagnosed	based	on	the	STIR	T2-weighted	images	detecting	myocardial	oedema	and	
regional	wall	motion	in	the	mid-cavity	or	apical	distribution	with	no	myocardial	LGE,	
all	 in	 accordance	 with	 the	 modified	 Mayo	 Clinic	 criteria.(156)	 	 Dilated	
cardiomyopathy,	 hypertrophic	 cardiomyopathy	 and	 cardiac	 amyloidosis	 were	
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Baseline	 patient	 characteristics,	 conventional	 risk	 markers	 and	 CMR	 findings	 are	
described	 according	 to	 the	 diagnostic	 groups.	 Data	 for	 continuous	 variables	 are	
presented	 in	 mean	 ±	 standard	 deviation	 or	 medians	 as	 appropriate.	 Categorical	
variables	 are	 presented	 as	 frequencies	 and	 percentages.	 Normally	 distributed	
continuous	 variables	 were	 compared	 using	 one-way	 analysis	 of	 variance	 with	
(ANOVA)	with	Bonferroni	correction	for	multiple	comparisons.	Continuous	variables	
that	 were	 not	 normally	 distributed	 were	 compared	 by	 Kruskal–Wallis	 tests.	 In	
univariate	analyses	the	association	of	time	variables	to	mortality	was	assessed	using	
Kaplan–Meier	 curves	 and	 the	 log-rank	 test.	 Univariable	 and	 multivariable	
associations	of	 risk	covariates	with	mortality	were	assessed	using	Cox	proportional	
hazard	 regression	 analyses.	 Only	 variables	 with	 a	 p	 value<0.05	 in	 univariable	
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analyses	were	used	in	multivariable	model.	SPSS	Version	23	(IBM	Corp,	Armonk,	NY)	



















	consecutive patients scanned from September 2011 to
December 2015. Patients were identified either pre-
senting with STEMI or non-STEMI. Nonobstructed
coronaries were defined as thrombosis in MI III flow
and <50% stenosis in any coronary artery (3).
Troponin T level <14 ng/l was considered normal. The
typical rise or fall of troponin T was used for the
diagnosis of acute MI. (9) False-positive troponin
possibilities included a single troponin elevation
(<5! upper limit of normal) that was not repeated
during admission or if a single elevated troponin was
followed by a second normal troponin level within 24
h was excluded from study (2). The study was
reviewed and approved by the local institutional re-
view board.
CMR PROTOCOL. CMR was performed at 1.5-T (Mag-
netom Avanto, Siemens Healthineers, Erlangen, Ger-
many). A comprehensive CMR protocol was carried
out, including cine, T2-weighted (myocardial edema),
and early and late gadolinium enhancement (LGE)
imaging (23). In particular, cine images were per-
formed using a steady-state free-precession sequence
acquired in 3 long-axis planes and a stack of short-
axis images covering the left ventricle, and T2-
weighted short T1 inversion recovery (T2-STIR)
sequence images were acquired in the same short-
and long-axis planes as the cine images with standard
parameters, as previously described (24,25). Intrave-
nous gadolinium-chelate contrast agent (gadobutrol)
was administered at a dose of 0.1 mmol/kg–1 of body
weight. Images were acquired 2 to 3 min after contrast
injection (early gadolinium), whereas LGE images
were acquired 15 to 20 min after contrast injection
using a standard inversion recovery segmented
gradient echo sequence, as previously described
(24,25).
CMR ANALYSIS. All CMR studies were analyzed and
reported by a consultant with >15 years of CMR
experience and with ESC CMR level 3 certification
(C.B.D.). Diffuse and focal myocardial edema was
analyzed using both the early gadolinium and the T2-
STIR images. Myocardial edema was considered pre-
sent when the ratio of signal intensity between the
myocardium and the mean signal intensity of the
skeletal muscle was >2 on T2-STIR images, according
to the Lake Louise criteria (26). Early gadolinium
enhancement ratio used for assessment of hyperemia
was evaluated as previously described (26). Patients
were grouped into 4 categories based on their CMR
characteristics: MI (embolic/spontaneous recanaliza-
tion), myocarditis, cardiomyopathy, and normal
CMR. The latter corresponded to a structurally
normal heart, defined as no regional wall motion
abnormality (RWMA) (except for dyssynchrony sec-
ondary to bundle branch block), no myocardial
edema, and no myocardial LGE (scarring) (except
nonspecific LGE in left ventricular [LV]/right ven-
tricular [RV] insertion points). Myocarditis was diag-
nosed based on fulfilling 2 of 3 Lake Louise Criteria:
T2-STIR sequences detecting myocardial edema;
early gadolinium sequences detecting hyperemia; or
epicardial or mid-myocardial LGE, as previously
described (26). MI was diagnosed based on territorial













Age, yrs 56 # 17 62 # 12 42 # 17 64 # 12 54 # 16 <0.001
Women 48 56 23 61 54 <0.001
Family history of IHD 3 2 4 1 3 0.57
Diabetes 6 8 5 6 4 0.64
Hypertension 13 16 9 14 14 0.54
History of smoking 7 4 5 10 7 0.32
BMI 26.5 27.3 26.5 25.7 26.4 0.18
Median troponin T, ng/l 497 660 924 419 202 0.03
Presentation as STEMI 19 19 19 25 14 0.29
Median interval, days
(presentation and CMR)
37 37 21 12 47 <0.001
Median follow-up, days 1,262 1,246 1,336 1,231 1,276 0.09
All-cause mortality 6 (22) 4 (4) 2 (2) 15 (14) 2 (2) <0.001
Values are mean # SD, n, or n (%).
BMI ¼ body mass index; CM ¼ cardiomyopathy; CMR ¼ cardiac magnetic resonance; IHD ¼ ischemic heart
disease; MI ¼ myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.
FIGURE 2 Age as a Marker of Mortality
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Log rank 23.2, p < 0.001
<40 yrs 40-59 yrs 60-79 yrs >79 yrs
Kaplan-Meier curves showing the risk of mortality according to age group.
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Figure	 4-3	 Age	 as	 a	 marker	 of	 mortality. Kaplan-Meier curves showing the risk of 


















subendocardial or transmural LGE. Takotsubo car-
diomyopathy was diagnosed based on the T2-STIR
images detecting myocardial edema and regional
wall motion in the mid-cavity or apical distribution
with no myocardial LGE, all in accordance with the
modified Mayo Clinic criteria (27). Dilated cardiomy-
opathy, hypertrophic cardiomyopathy, and cardiac
amyloidosis were detected based on specific tissue
characterization characteristics, and all were grouped
under cardiomyopathy together with Takotsubo car-
diomyopathy (15). The extent of LGE and myocardial
edema was quantified by calculating the number of
segments involved (20).
STUDY PRIMARY ENDPOINT. The endpoint of the
present study was all-cause mortality. Patient-related
data were collected directly from medical records.
Follow-up was performed centrally by analyzing the
mortality data obtained from the National Health
Service summary care records. Data were collected
and interpreted by 1 of the primary investigators
(A.G.D., A.B., E.D.G., or G.B.) in all cases.
STATISTICAL ANALYSIS. Baseline patient character-
istics, conventional risk markers, and CMR findings
are described according to the diagnostic groups. Data
for continuous variables are presented as mean !
standard deviation or median as appropriate. Cate-
gorical variables are presented as frequencies and
percentages. Normally distributed continuous vari-
ables were compared using 1-way analysis of variance
with Bonferroni correction for multiple comparisons.
Continuous variables that were not normally distrib-
uted were compared by Kruskal-Wallis tests. In uni-
variate analyses, the association of time variables to
mortality was assessed using Kaplan-Meier curves
and the log-rank test. Univariable and multivariable
associations of risk covariates with mortality were
assessed using Cox proportional hazard regression
analyses. Only variables with p < 0.05 in univariable
analyses were used in multivariable model. SPSS
version 23 (IBM Corp., Armonk, New York), was used
for statistical analysis. Probability values were 2-
sided, and values of p < 0.05 were considered sig-
nificant. Because of a paucity of mortality data on the
MINOCA subgroups, post hoc power calculation was
performed based on the study findings.
RESULTS
A total of 11,757 patients underwent emergency or
urgent coronary angiography during the recruitment
period, of which 410 patients with suspected MINOCA
underwent CMR assessment. Two percent (n ¼ 8)
were excluded because of incomplete protocol and
3% (n ¼ 14) because of coronary artery disease that
was deemed >50% stenosis, thereby leaving a study
sample size of 388. CMR was able to identify a cause
for the troponin rise in 74% of cases. Clinical char-
acteristics of the overall population (n ¼ 388) and for
separate patient groups based on the CMR diagnosis
are summarized in Table 1. There was a low preva-
lence of cardiovascular risk factors (hypertension,
diabetes, hyperlipidemia, smoking, and family his-
tory), with no difference across groups. The median
time delay between acute presentation and CMR was
37 days. Thirty-seven of our patients underwent a
FIGURE 3 ECG at Presentation
0.00
0 500 1000
















Log rank 7.4, p = 0.007
NSTE-ACS STEMI
Kaplan-Meier curves showing the risk of mortality according to
presence or absence of ST-segment elevation on the
presenting ECG. ECG ¼ electrocardiogram; NSTE-ACS ¼
non-ST-segment elevation-acute coronary syndrome;
STEMI ¼ ST-segment elevation myocardial infarction.













iEDV, ml/m2 81 78 83 90 74 <0.001
iESV, ml/m2 34 30 32 47 26 <0.001
iSV, ml/m2 47 48 50 43 48 <0.001
LVEF 61 63 62 52 67 <0.001
iLV mass, g/m2 66 63 67 75 59 <0.001
RWMA 39 59 31 59 6 <0.001
LGE 58 100 94 34 6 <0.001
No. of LGE segments 1 (0–2) 1 (1–2) 3 (2–4) 0 (0–1) 0 <0.01
Myocardial edema, % 34 52 52 34 0 <0.001
No. of edema segments 0 (0–2) 1 (0–2) 2 (0–4) 0 (0–5) 0 <0.01
Values are % or median (interquartile range).
iEDV ¼ indexed end-diastolic volume; iESV ¼ indexed end-systolic volume; iLV ¼ indexed left ventricular;
IQR ¼ interquartile range; iSV ¼ indexed stroke volume; LGE ¼ late gadolinium enhancement; LVEF ¼ left
ventricular ejection fraction; MI ¼ myocardial infarction; RWMA ¼ regional wall motion abnormality; other
abbreviation as in Table 1.
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iEDV, ml/m2 81 78 83 90 74 <0.001
iESV, ml/m2 34 30 32 47 26 <0.001
iSV, ml/m2 47 48 50 43 48 <0.001
LVEF 61 63 62 52 67 <0.001
iLV mass, g/m2 66 63 67 75 59 <0.001
RWMA 39 59 31 59 6 <0.001
LGE 58 100 94 34 6 <0.001
No. of LGE segments 1 (0–2) 1 (1–2) 3 (2–4) 0 (0–1) 0 <0.01
Myocardial edema, % 34 52 52 34 0 <0.001
No. of edema segments 0 (0–2) 1 (0–2) 2 (0–4) 0 (0–5) 0 <0.01
Values are % or median (interquartile range).
iEDV ¼ indexed end-diastolic volume; iESV ¼ indexed end-systolic volume; iLV ¼ indexed left ventricular;
IQR ¼ interquartile range; iSV ¼ indexed stroke volume; LGE ¼ late gadolinium enhancement; LVEF ¼ left
ventricular ejection fraction; MI ¼ myocardial infarction; RWMA ¼ regional wall motion abnormality; other
abbreviation as in Table 1.
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scan within 2 weeks of presentation. In a median
follow-up of 1,262 days (3.5 years), the overall all-
cause mortality was 5.7%.
CONVENTIONAL RISK FACTORS. Age. The mean
age of the total population was 56 ! 17 years. Kaplan-
Meier curves were drawn showing the risk of mor-
tality according to the different age categories (<40,
40 to 59, 60 to 79, and >79 years). There was a strong
association between increasing age and mortality
(log-rank test: 23.2; p < 0.001) (Figure 2).
Sex. Women comprised 48% of the total cohort and
98% of the patients diagnosed with Takotsubo car-
diomyopathy were women. There was no significant
association between sex and mortality in the overall
cohort (log-rank test: 2.5; p ¼ 0.10).
Electrocardiogram at presentation (STEMI or NSTE-ACS).
Nineteen percent of our study population presented
with ST-segment elevation on the 12-lead electro-
cardiogram (ECG). Kaplan-Meier curves were drawn
showing the risk of mortality according to the ECG
presentation as ST-segment elevation or no ST-
segment elevation. There was a strong association
between ECG presentation as ST-segment elevation
and mortality (log-rank test: 7.4; p ¼ 0.007)
(Figure 3).
CMR CHARACTERISTICS AND DIAGNOSIS. The CMR
characteristics are described according to diagnosis
groups (Table 2).
MI was the most prevalent diagnosis (25%, 97 of
388 patients), followed by myocarditis (25%, 96 of
388) and cardiomyopathy 25%, whereas 26% had a
structurally normal heart and were grouped into the
normal CMR category.
LV volumes. In the overall cohort, the mean indexed
end-diastolic volume (iEDV) was 81 ml/m2. On Bon-
ferroni correction, the iEDV in the cardiomyopathy
was significantly higher than the MI and normal CMR
categories.
LV ejection fraction. The mean left ventricular ejection
fraction (LVEF) for the entire cohort was 61%. On
Bonferroni correction, the LVEF in the cardiomyopa-
thy was significantly lower than the MI, myocarditis,
and normal CMR categories. In addition, the LVEF in
the myocarditis category was significantly lower than
the normal CMR category.
RWMA. Overall, 39% of patients had RWMA. The
normal CMR category had RWMA secondary to
bundle branch block on ECG.
Myocardial edema. The overall prevalence of focal
myocardial edema was 34% based on T2 STIR or early
gadolinium enhancement. Focal myocardial edema
was absent in patients with normal CMR. Additional
analysis of the normal CMR cohort revealed no
evidence of diffuse myocardial injury in any of the
patients.
LGE. LGE was present in 58% of the entire cohort. Six
percent of patients with normal CMR had evidence of
LGE in the LV/RV insertion points only, which
currently is considered a nonspecific finding.
CARDIOMYOPATHY SUBGROUP ANALYSIS. In the
cardiomyopathy group, 43% had Takotsubo cardio-
myopathy, 29% dilated cardiomyopathy, and 18%
hypertrophic cardiomyopathy. The remaining had
infiltrative cardiomyopathy (amyloidosis; n ¼ 4), hy-
pertensive heart disease (n ¼ 4), and valvular heart
disease (n ¼ 2) and were grouped as other. There was
no statistically significant difference in the mean age
and presentation as STEMI; however, there was a
significant difference in sex among the different car-
diomyopathy subgroups. There was also a significant
difference in the CMR parameters among the
different cardiomyopathy subgroups (Table 3).
TREATMENT BEFORE CMR. Aspirin, other anti-
platelets, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, beta-blocker, and statin
use in the overall cohort was 93%, 61%, 66%, 65%,
and 57%, respectively. There was no significant











Age, yrs 68 ! 10 63 ! 13 60 ! 17 60 ! 12 0.05
Women 98 32 47 33 <0.001
STEMI 38 18 24 0 0.07
iEDV, ml/m2 77 128 67 81 <0.001
iESV, ml/m2 35 87 20 36 <0.001
iSV, ml/m2 42 41 48 44 0.298
LVEF 56 33 70 59 <0.001
iLV mass, g/m2 61 85 87 88 <0.001
Mortality 6 5 0 3 <0.01
Values are mean ! SD or n.
DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; TMC ¼ Takotsubo cardiomyopathy;
other abbreviations as in Tables 1 and 2.












Aspirin 95 92 91 92 0.81
Other antiplatelet 61 59 60 63 0.31
ACE inhibitor/ARB 65 66 69 66 0.92
Beta-blocker 65 64 71 62 0.58
Statin 62 53 59 56 0.66
Values are n.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; other abbreviations as in Table 1.
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with	worst	 prognosis	 identified	 in	 the	 cardiomyopathy	 group	 (15%	mortality).	 The	
mortality	 rate	 in	 the	 different	 groups	 was:	 cardiomyopathy	 15%,	 MI	 group	 4%,	
myocarditis	group	2%,	and	the	normal	group	2%	(p=0.001).	
Kaplan-Meier	 curves	 were	 drawn	 showing	 the	 risk	 of	 mortality	 according	 to	 the	
different	CMR	diagnosis,	showing	a	strong	association	between	CMR	categories	and	
mortality	(log	rank	19.9,	p<0.001).	Figure	4-5	
difference in the use of medications among the
different diagnostic categories (Table 4).
PROGNOSIS IN DIFFERENT CMR CATEGORIES.
In a median follow-up of 1,262 days (3.5 years), the
overall all-cause mortality was 5.7%, with worst
prognosis identified in the cardiomyopathy group
(15% mortality). The mortality rate in the different
groups was: cardiomyopathy 15%; MI group 4%;
myocarditis group 2%; and normal 2% (p ¼ 0.001).
Kaplan-Meier curves were drawn showing the risk
of mortality according to the different CMR
diagnoses, showing a strong association between
CMR categories and mortality (log-rank test: 19.9;
p < 0.001) (Figure 4A). An additional Kaplan-Meier
curve was drawn for Takotsubo cardiomyopathy,
showing a significantly higher mortality in Takotsubo
group compared with any other diagnosis (log-rank
test: 7.3; p ¼ 0.011) (Figure 4B).
PREDICTORS OF ALL-CAUSE MORTALITY. Age, pre-
sentation with ST-segment elevation on ECG, iEDV,
log troponin, LVEF, and CMR diagnosis of cardiomy-
opathy were significant univariable predictors of
mortality (p < 0.05 considered significant for uni-
variate analysis). In a multivariable model, only CMR
diagnosis of cardiomyopathy (hazard ratio: 3.0; 95%
confidence interval: 1.08 to 8.37; p ¼ 0.034) and ECG
presentation with ST-segment elevation (hazard ra-
tio: 3.10; 95% confidence interval: 1.27 to 7.68; p ¼
0.013) remained significant (Table 5).
MORTALITY RISK MARKERS (ECG PRESENTATION
WITH ST-SEGMENT ELEVATION D CMR DIAGNOSIS).
A risk assessment tool for predicting mortality was
constructed on the basis of 2 variables: CMR diagnosis
of cardiomyopathy and ECG presentation with ST-
segment elevation. The first group was defined as
242 patients with any other CMR diagnosis except
cardiomyopathy and presentation as NSTE-ACS. The
second group consisted of 122 patients with only 1 of
the factors altered (i.e., either a CMR diagnosis of
cardiomyopathy or ECG presentation with ST-
segment elevation). Finally, the third group
included 24 patients with CMR diagnosis of cardio-
myopathy and ECG presentation with ST-segment
elevation. The mortality rates in these 3 groups
were 1.6% (4 of 242), 10.6% (13 of 122), and 20.8% (5 of
24), respectively. Kaplan-Meier curves were drawn
showing the risk of mortality in these 3 groups,
showing a strong association between number of risk
markers and mortality (log-rank test: 23.6; p<0.001)
(Figure 5).
POST HOC POWER CALCULATION. Using mortality
of 15% in the cardiomyopathy group versus 3% for the
rest of the cohort with an alpha of 0.05, our study
demonstrated 95% power.
DISCUSSION
This is the largest cohort to date of patients with
MINOCA assessed with CMR, and the first study to our
FIGURE 4 Cumulative Mortality According to CMR diagnosis
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A
(A) Kaplan-Meier curves showing the risk of mortality according to CMR
diagnosis (MI vs. myocarditis vs. cardiomyopathy vs. normal). (B) Kaplan-
Meier curves showing the risk of mortality according to CMR diagnosis of
Takotsubo cardiomyopathy versus any other diagnosis. MI ¼ myocardial
infarction; other abbreviation as in Figure 1.
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An	 additional	 Kaplan-Meier	 curve	 was	 drawn	 for	 Takotsubo	 cardiomyopathy,	
showing	a	significantly	higher	mortality	 in	Takotsubo	group	compared	to	any	other	
diagnosis	(log	rank	7.3,	p=0.011).	Figure	4-6	
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0.013) remained significant (Table 5).
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(A) Kaplan-Meier curves showing the risk of mortality according to CMR
diagnosis (MI vs. myocarditis vs. cardiomyopathy vs. normal). (B) Kaplan-
Meier curves showing the risk of mortality according to CMR diagnosis of
Takotsubo cardiomyopathy versus any other diagnosis. MI ¼ myocardial
infarction; other abbreviation as in Figure 1.
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Age,	presentation	with	ST-elvation	on	ECG,	 iEDV,	 log	 troponin,	 LV	ejection	 fraction	
and	 CMR	 diagnosis	 of	 cardiomyopathy	 were	 significant	 univariable	 predictors	 of	
mortality	 (p<0.05	 considered	 significant	 for	 univariate	 analysis).	 In	 a	multivariable	
model	 only	 CMR	 diagnosis	 of	 cardiomyopathy	 (hazard	 ratio	 3.0,	 95%	CI	 1.08-8.37,	
	 86	
p=0.034)	 and	 presentation	 with	 ST-elevation	 (hazard	 ratio	 3.1,	 95%	 CI	 1.27-7.68,	
p=0.013)	remained	significant.	Table	4-8.		
Table	 4-8	 Predictors	 of	mortality	 –univariate	 and	multivariate	 logistic	 regression	
analysis	knowledge to assess the prognostic role of CMR and
conventional risk factors in patients with MINOCA.
The main findings are as follows: 1) CMR can identify
a diagnosis in 3 of 4 patients presenting with MINOCA
and suitable for CMR assessment; 2) CMR diagnosis of
cardiomyopathy (imaging) and ECG presentation with
ST-segment elevation (conventional risk marker)
were the strongest predictors of mortality; and 3) a
combined risk assessment tool using the 2 parameters
(cardiomyopathy and ECG presentation with ST-
segment elevation) provides further risk stratifica-
tion in these patients.
DIAGNOSTIC ROLE OF CMR IN MINOCA. It is impor-
tant to identify a cause for MINOCA to guide ongoing
management and provide patient guidance. As a
noninvasive imaging technique, CMR (done at a me-
dian of 37 days from presentation) is able to identify a
diagnosis in these patients in up to 3 of 4 cases. The
diagnostic role of CMR in this patient group has been
demonstrated in a small number of previous studies
with smaller sample sizes (11–17); however, the diag-
nostic yield of CMR in the literature was disparate,
ranging from as low as 30% to as high as 90% (11–17).
The variation in the diagnostic yield in the literature
can be explained by the use of incomplete CMR pro-
tocol (edema imaging was not always included) as
well as the timing of the test, which sometimes occurs
several months after the acute event, leading to the
resolution of the reversible cardiac abnormalities
(13,18).
In our cohort, the most common diagnosis was MI
(25%, n ¼ 97), closely followed by myocarditis (25%,
n ¼ 96) and cardiomyopathy (25%); however, the
literature suggests that myocarditis is much more
common than MI (10–13,15), contrary to our result.
The mean age in our study was much higher
compared with the other studies on MINOCA, which
may have contributed to the higher prevalence of MI
(14,15). Another possible explanation could be the use
of established criteria (Lake Louise Criteria) for
diagnosing myocarditis (26), in addition to an inclu-
sion cutoff of <50% coronary artery stenosis (10–15).
PROGNOSTIC ROLE OF CMR IN MINOCA. Of all the
CMR parameters examined (including LV, LV, and LV
mass; myocardial edema; LGE; and the overall CMR
diagnosis), a CMR diagnosis of cardiomyopathy was
associated with the worst prognosis (15% mortality).
On a multivariable analysis involving both traditional
markers and CMR characteristics, CMR-derived diag-
nosis of cardiomyopathy remained significant as an
independent predictor of mortality.
Among the other CMR parameters assessed, LVEF
and LV indexed end-diastolic volume were significant
univariable predictors of mortality, but not in multi-
variable analysis. These findings are particularly
useful in justifying the role of CMR tissue character-
ization in MINOCA.
The cardiomyopathy group in our study was a
heterogenous group, with Takotsubo cardiomyopathy
being the most common (43% of the cardiomyopathy
group). Takotsubo cardiomyopathy had the worst
prognosis over a median follow-up of 3.5 years (15%
overall mortality) when compared with any other
CMR diagnosis. The findings are comparable to the
recent study by Templin et al. (21) in which Takotsubo
cardiomyopathy had a mortality of 5.6% per patient-
year in long-term follow-up. CMR not only helps di-
agnose, it may also help identify the high risk
Takotsubo cardiomyopathy cases by delineating the
amount of myocardial edema, RV involvement,
thrombus, and LV outflow tract obstruction. CMR-
derived apico-basal myocardial edema gradient may
be used as a marker of malignant arrhythmia risk (28).
CONVENTIONAL RISK FACTORS FOR PROGNOSIS
ASSESSMENT. Of all the risk factors assessed, ECG
presentation with ST-segment elevation was an in-
dependent predictor of mortality. Age and log-peak
troponin were univariable predictors of mortality,
but not in multivariable analysis. Gender was not
associated with mortality. The finding on peak
troponin is particularly important because it is in
contrary to the regular practice. High peak troponin
level is often used as an arbitrary prognostic marker
because of its evidence from ACS trials (29). The
importance of the presentation ECG is a novel finding
TABLE 5 Univariable and Multivariable Association for Mortality





Lower Upper Lower Upper
Age group 0.008 2.046 1.203 3.48 0.100 1.645 0.908 2.978
Sex 0.302 1.564 0.669 3.659
BMI 0.484 0.968 0.884 1.06
Log-peak troponin 0.041 0.509 0.267 0.971 0.094 0.565 0.290 1.101
STEMI 0.01 3.059 1.307 7.157 0.013 3.125 1.271 7.684
iEDV 0.008 1.016 1.004 1.028 0.258 1.01 0.993 1.028
LVEF 0.001 0.958 0.936 0.981 0.851 0.996 0.96 1.034
RWMA 0.132 1.905 0.823 4.41
LGE 0.161 0.544 0.233 1.274
Edema 0.228 0.542 0.20 1.469
MI 0.472 0.672 0.227 1.986
Myocarditis 0.098 0.293 0.068 1.253
CM 0.001 5.628 2.361 13.417 0.034 3.013 1.084 8.373
Normal 0.091 0.285 0.067 1.219
CI ¼ confidence interval; CM ¼ cardiomyopathy; other abbreviations as in Tables 1 and 2.
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patients	 with	 only	 one	 of	 the	 factors	 altered	 i.e.	 either	 a	 CMR	 diagnosis	 of	
cardiomyopathy	or	 presentation	with	 ST-elevation	on	 ECG.	 Finally,	 the	 third	 group	
	 87	
included	24	patients	with	CMR	diagnosis	of	cardiomyopathy	and	presentation	with	
ST-elevation	 on	 ECG.	 The	 mortality	 rates	 in	 these	 3	 groups	 were	 (4/242)	 1.6%,	
(13/122)	 10.6%,	 and	 (5/24)	 20.8%.	 respectively.	 Kaplan-Meier	 curves	 were	 drawn	
showing	 the	 risk	 of	 mortality	 in	 these	 3	 groups,	 showing	 a	 strong	 association	
between	number	of	risk	marker	and	mortality	(log	rank	23.6,	p < 0.001).	Figure	4-7.	
because it is often overlooked while managing pa-
tients with MINOCA.
CLINICAL IMPLICATIONS. Our findings strengthen
the evidence that CMR is a clinically relevant nonin-
vasive imaging modality for the assessment of pa-
tients presenting with MINOCA. In a previous study,
we demonstrated that CMR in MINOCA leads to a
change in diagnosis in 54% and change in manage-
ment in 41% of patients (18). The current study re-
inforces the effect of CMR because a diagnosis of
cardiomyopathy is associated with worst prognosis.
Any other diagnosis except cardiomyopathy had a
relatively low mortality (2% to 4%), thereby putting
patients in a good prognostic category.
Currently, there is no risk stratification algorithm
for patients presenting with MINOCA. The results of
our study suggest that ECG at presentation and CMR
diagnosis might be useful predictors for risk stratifi-
cation. This should be explored further and
confirmed in larger multicenter studies.
STUDY LIMITATIONS. Several limitations merit
consideration. This is a single-center study with
relatively limited sample size. Although our study
was designed to represent a real-world population,
we potentially might have excluded higher-risk pa-
tients with contraindications to CMR (e.g., creati-
nine clearance <30 ml/min, intracardiac devices).
Our study did, however, include a broad range of
consecutive patients with MINOCA from a large
catchment area, and only a limited number (2%) of
patients were excluded from CMR. There may have
been a referral bias because the study included pa-
tients with MINOCA, referred for a CMR by the
physician providing the care; however, our regular
FIGURE 5 Prognostic Role of CMR Diagnosis and ECG in MINOCA
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(Left) In a population of patients presenting with MINOCA, CMR identified 4 main categories: cardiomyopathy (Takotsubo), myocarditis,
myocardial infarction, and normal. In the Takotsubo cardiomyopathy case, there is transmural edema of the mid-apical segments but no late
gadolinium enhancement (LGE); in the myocarditis case, there is diffuse edema with diffuse patchy epicardial and midwall LGE (black arrow),
subsequent endomyocardial biopsy confirmed giant cells myocarditis; in the myocardial infarction case, there is focal transmural edema of
the apical anterolateral wall with corresponding focal transmural LGE (black arrow). No abnormalities were noted in the normal case.
(Right) Kaplan-Meier curves showing the risk of mortality according to risk group (group A: any CMR diagnosis except cardiomyopathy and
presentation as NSTE-ACS; group B: CMR diagnosis of cardiomyopathy or presentation as STEMI; group C: CMR diagnosis of cardiomyopathy
and presentation as STEMI). Abbreviations as in Figures 1 and 3.
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This	 is	 the	 largest	 to	date	cohort	of	MINOCA	patients	assessed	with	CMR,	and	 the	
first	 study	 to	 assess	 the	 prognostic	 role	 of	 CMR	 and	 conventional	 risk	 factors	 in	
patients	 with	 MINOCA.	 The	 main	 findings	 are	 as	 follows:	 1)	 CMR	 can	 identify	 a	
diagnosis	in	3/4	patients	presenting	with	MINOCA	and	suitable	for	CMR	assessment,	
2)	 CMR	diagnosis	 of	 cardiomyopathy	 is	 the	 strongest	 CMR	marker	 associated	with	
mortality,	 3)	 among	 the	 conventional	 risk	 markers,	 ECG	 presentation	 with	 ST-





It	 is	 important	 to	 identify	 a	 cause	 for	 MINOCA	 in	 order	 to	 guide	 ongoing	
management	and	provide	patient’s	guidance.	As	a	non-invasive	 imaging	 technique,	
CMR	is	able	to	identify	a	diagnosis	in	these	patients	in	up	to	3/4	cases,	irrespective	of	
timing	 of	 scan.	 The	 diagnostic	 role	 of	 CMR	 in	 this	 patient	 group	 has	 been	
demonstrated	in	a	small	number	of	previous	studies	with	smaller	sample	sizes.	(7-11)	
However,	the	diagnostic	yield	of	CMR	in	the	literature	was	disparate,	ranging	from	as	
low	as	30%	to	as	high	as	90%.	 (29,30,32–34,36,37)	 	The	variation	 in	 the	diagnostic	
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yield	 in	 the	 literature	 can	 be	 explained	 by	 the	 use	 of	 incomplete	 CMR	 protocol	
(edema	 imaging	not	always	 included)	as	well	as	 the	timing	of	 the	test	 ,	 sometimes	




Myocarditis	 (25%,	 n=96)	 and	 cardiomyopathy	 (25%).	 However,	 the	 literature	
suggests	myocarditis	to	be	much	more	common	than	MI	(10-13,	15),	contrary	to	our	
result.	The	mean	age	in	our	study	was	much	higher	compared	to	the	other	studies	on	
MINOCA	 which	 may	 have	 contributed	 to	 the	 higher	 prevalence	 of	 MI.(29,32)	
Another	 possible	 explanation	 could	 be	 the	 use	 of	 established	 criteria	 (Lake	 Louise	




Of	 all	 the	 CMR	 parameters	 examined	 (including	 LV	 size,	 LV	 function,	 LV	 mass,	
myocardial	 oedema,	 LGE	 and	 the	 overall	 CMR	 diagnosis),	 a	 CMR	 diagnosis	 of	
cardiomyopathy	 was	 associated	 with	 the	 worst	 prognosis	 (15%	 mortality).	 On	 a	
multivariable	 analysis	 involving	 both	 traditional	 markers	 and	 CMR	 characteristics,	
CMR-derived	 diagnosis	 of	 cardiomyopathy	 remained	 significant	 as	 an	 independent	
predictor	of	mortality.			
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Among	 the	 other	 CMR	 parameters	 assessed,	 LV	 ejection	 fraction	 and	 LV	 indexed	
end-diastolic	 volume	were	 significant	univariable	predictors	of	mortality	but	not	 in	
multivariable	analysis.	These	 findings	are	particularly	useful	 in	 justifying	the	role	of	
CMR	tissue	characterization	in	MINOCA.		
The	cardiomyopathy	group	 in	our	study	was	a	heterogenous	group	with	Takotsubo	
cardiomyopathy	 being	 the	 most	 common	 (43%	 of	 the	 cardiomyopathy	 group).	
Takotsubo	cardiomyopathy	had	the	worst	prognosis	over	a	median	follow	up	of	3.5	
years	 (15%	 overall	 mortality)	 when	 compared	 to	 any	 other	 CMR	 diagnosis.	 The	
findings	 are	 comparable	 to	 the	 recent	 study	 by	 Templin	 et	 al.	 in	which	 Takotsubo	
cardiomyopathy	 had	 a	 mortality	 of	 5.6%	 per	 patient-year	 in	 long	 term	 follow	
up.(171)	CMR	not	only	helps	in	diagnosis	but	it	may	also	help	in	identifying	the	high	
risk	 Takotsubo	 cardiomyopathy	 cases	 by	 delineating	 the	 amount	 of	 myocardial	
oedema,	 RV	 involvement,	 thrombus,	 LV	 outflow	 tract	 obstruction.	 CMR	 derived	




Out	of	 all	 the	 risk	 factors	 assessed,	 presentation	with	 ST-elevation	on	ECG	was	 an	
independent	 predictor	 of	 mortality.	 Age	 and	 log	 peak	 troponin	 were	 univariable	
predictors	of	mortality	but	not	in	multivariable	analysis.	Gender	was	not	associated	
with	 mortality.	 The	 finding	 on	 peak	 troponin	 is	 particularly	 important	 as	 it	 is	 in	
contrary	 to	 the	 regular	 practice.	 	 High	 peak	 troponin	 level	 is	 often	 used	 as	 an	
arbitrary	prognostic	marker	due	to	its	evidence	from	acute	coronary	syndrome	trials.	
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Our	 findings	 strengthen	 the	evidence	 that	CMR	 is	 a	 clinically	 relevant	non-invasive	
imaging	 modality	 for	 the	 assessment	 of	 patients	 presenting	 with	 MINOCA.	 In	 a	
previous	 study	we	 have	 demonstrated	 that	 CMR	 in	MINOCA	 leads	 to	 a	 change	 in	
diagnosis	 in	 54%	 and	 change	 in	 management	 in	 41%.	 (17)	 The	 current	 study	
reinforces	 the	 impact	of	CMR,	as	a	diagnosis	of	 cardiomyopathy	 is	associated	with	
worst	 prognosis.	 Any	 other	 diagnosis	 except	 cardiomyopathy	 had	 a	 relatively	 low	
mortality	(2-4%)	thereby	putting	them	in	a	good	prognostic	category.		
	
This	 is	 the	 largest	cohort	 to	date	 to	confirm	the	diagnostic	 role	of	CMR	 in	patients	
with	MINOCA	and	the	first	study	looking	at	the	prognostic	role	of	CMR	in	this	patient	
population.		
Currently,	 there	 is	 no	 risk	 stratification	 algorithm	 for	 patients	 presenting	 with	
MINOCA.	 The	 results	 of	 our	 study	 suggest	 that	 ECG	 at	 presentation	 and	 CMR	





Several	 limitations	merit	 consideration.	 This	 is	 a	 single	 centre	 study	with	 relatively	
limited	 sample	 size.	 Although	 our	 study	 was	 designed	 to	 represent	 a	 real-world	
population,	 we	 potentially	 might	 have	 excluded	 higher-risk	 patients	 with	
contraindications	 to	 CMR	 (e.g.,	 creatinine	 clearance	 <30	 ml/min	 and	 intracardiac	
devices).	 However,	 our	 study	 included	 a	 broad	 range	 of	 consecutive	 MINOCA	
patients	 from	a	 large	 catchment	 area,	 and	only	 a	 limited	number	 (2%)	 of	 patients	
were	excluded	from	CMR.	There	may	have	been	a	referral	bias	as	the	study	included	
MINOCA	patients,	referred	for	a	CMR	by	the	physician	providing	the	care.	However,	
our	 regular	 clinical	 practice	 at	 the	 Bristol	 Heart	 Institute	 includes	 CMR	 in	 patients	
presenting	 with	 MINOCA.	 The	 CMR	 was	 performed	 at	 a	 median	 of	 37days	 from	
presentation	and	this	may	have	impacted	the	diagnostic	pick	up	rate	as	well	as	the	
prevalence	 of	 myocardial	 edema.	 Nevertheless,	 our	 study	 showed	 a	 significant	





images	 analysis.	 Lastly,	 myocardial	 biopsy	 was	 not	 carried	 out	 in	 these	 patients.	






diagnosis	 in	 almost	 3/4	 of	 cases.	 Among	 the	 conventional	 risk	 factors	 and	 CMR	
characteristics,	 ST-segment	 elevation	 on	 presentation	 ECG	 and	 CMR	 diagnosis	 of	
cardiomyopathy	 were	 independent	 predictors	 of	 mortality.	 Combined	 analysis	 of	
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LV	EF	%	 49(±10)	 53(±8)	 0.28	
EDV	ml	 161(±21)	 141(±29)	 0.05	
ESV	ml	 84(±23)	 69(±26)	 0.15	
SV	ml	 78(±15)	 72(±10)	 0.2	
LV	Mass	gm	 152(±20)	 128(±29)	 0.01	
Infarct	size	%	 22(±9)	 14(±10)	 0.04	
AAR	%	(T2STIR)	 34(±13)	 27(±10)	 0.12	
T1	Remote	ms	 1048(±19)	 1004(±33)	 <0.001	
T2	Remote	ms	 48(±2)	 48	(±3)	 0.8	
T1	core	ms	 1128(±60)	 1304(±67)	 <0.001	
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ROC analysis demonstrated an excellent AUC of 0.92(p<0.001) for remote native T1 
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compared using unpaired Student t tests or one-way anal-
ysis of variance with Bonferroni post hoc correction for 
between-groups comparisons, as appropriate. Continuous 
variables that were not normally distributed were compared 
by Kruskal–Wallis tests. R-values quoted are for Pearson’s 
correlation coefficient. The potential of quantitative T1-map-
ping to assess the TEI or viability on a segmental basis 
against the current gold standards of LGE were explored. 
The analysis was also performed as per each coronary artery 
territory. Interobserver (AGD and IH) and intraobserver 
(AGD) variability for segmental native T1 was assessed in 
20 patients (10 acute MI and 10 chronic MI patients), and 
expressed as intraclass correlation coefficient (ICC) and 95% 
confidence interval.
Segmental analysis run a risk of class effect due to the 
potential of multiple samples from the same patient. To 
nullify the class-effect a series of generalized linear mixed 
effect models, with the random intercept for each person and 
for each segment, were performed to assess the association 
between T1 mapping and viability/LGE TEI. The models 
were used to account for the fact that different segments 
from the same patient or same segment location from dif-
ferent patients may not behave independently. These models 
were conducted for both acute and chronic MI assessments. 
Receiver operating characteristic (ROC) analysis was per-
formed to identify area under curve (diagnostic accuracy) 
of native T1 as a marker of TEI by using corresponding 
LGE scoring (LGE score > 3) as the gold standard. Cut-off 
values of T1 relaxation times as a marker of viability were 
also calculated from the ROC curve. Statistical significance 
of the differences between ROC curves was assessed using 
the online calculator (http://www.vassa rstat s.net). To take 
into consideration potential within-subject interaction of 
segments, clustered ROC analysis was also conducted to 
assess the performance of native T1 to predict viability. Sig-
nificance was defined as two-tailed p < 0.05.
Results
The demographic and the CMR characteristics of the 
healthy control and the patient cohort (60 MI patients- 
acute and chronic MI subgroups) are presented in Table 1. 
The mean age of the healthy volunteers was 57 ± 13 years 
and 75% were male. The mean age was significantly lower 
in the acute MI group (61 ± 10 years versus 67 ± 10 years, 
p = 0.017) compared to the chronic MI group. In 5% (n = 3) 
of patients the T1 maps had artefacts or signal. To overcome 
this problem, the mapping images were repeated. Out of the 
960 segments analysed from patients with previous MI(acute 
and chronic), 286 segments had evidence of LGE. Sixteen 
of the 30 acute MI patients had microvascular obstruction 
(MVO) (53%).
Interobserver and intraobserver variability 
for segmental T1 measurement
There was excellent inter and intra-observer agreement for 
native segmental T1 measurement. The intraclass correlation 
coefficient (ICC) and 95% confidence interval were 0.968 
(0.958–0.976) for interobserver and 0.992(0.967–0.998) for 
intraobserver agreement respectively.
Fig. 1  CMR images from a 
54 year old with acute trans-
mural myocardial infarction 
in right coronary artery, a T1 
map of the short axis, b region 
of interest drawn in each of 
the segment with correspond-
ing native T1 value (blinded to 
LGE image), c LGE image in 
the short axis, d T1 map of the 
corresponding short axis with 
region of interest in the remote 
myocardium and infarct core 
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Table 1  Demographic/CMR 
characteristics table Characteristics Control (n = 20) Acute MI (n = 30) Chronic MI (n = 30) p-value (acute versus chronic)
Age (years) 57(± 13) 61(± 10) 67(± 10) 0.017
Female sex (%) 25% 20% 20% 1.0
Smoking (%) – 27 17 0.356
Hypertension (%) – 43 53 0.447
Diabetes (%) – 10 23 0.171
CMR
 LV EF (%) 66(± 7) 51(± 9) 51(± 13) 0.833
 EDV (ml) 146(± 35) 152(± 29) 167(± 56) 0.218
 ESV (ml) 51(± 18) 77(± 26) 85(± 48) 0.406
 SV (ml) 95(± 22) 75(± 13) 83(± 23) 0.144
 Infarct size (%) – 21(± 10) 16(± 12) 0.135
Fig. 2  a Scatter plot: chronic MI cohort showing native T1 value ver-
sus the TEI, b bar diagram with error bar(SD): Chronic MI cohort 
showing segmental native T1 value in LGE negative, LGE positive 
with viability and LGE segments with non-viability c scatter plot: 
Correlation between segmental T1 and Transmural extent of Infarct—
as per coronary artery territory in chronic MI d ROC curve: Chronic 
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Chronic MI
T1 mapping versus scar transmurality (TEI)
In patients with chronic MI, the segmental T1 correlated 
significantly with LGE TEI (R = 0.74, p < 0.001) Fig. 2a. 
The mean segmental T1 value for LGE negative segments 
(myocardial segments with no infarction) was 1031 ± 31 ms, 
LGE positive but viable (scar grade 1–3): 1103 ± 57 ms and 
LGE positive but non viable (scar grade 4): 1206 ± 118 ms. 
The mean segmental T1 in each of the 3 categories (no 
LGE, LGE positive but viable and LGE positive but non-
viable) were significantly different on a pairwise compari-
son with Bonferroni correction (p < 0.01) Fig. 2b. The mean 
native T1 in the infarct core and remote myocardium were 
1171 ± 76 ms and 1005 ± 19 ms respectively Table 2.
When grouping the segments into coronary artery ter-
ritories, the correlation between native T1 and LGE TEI for 
RCA, LCx and LAD territories were R = 0.77, 0.80, 0.69 
respectively(p < 0.001) Fig. 2c.
T1 mapping as a marker of transmurality of infarction
Native T1 mapping showed excellent diagnostic accu-
racy in predicting transmural LGE ≥ 75% - AUC-0.88(CI 
0.77–0.99,p < 0.001) Fig. 2d. A cut-off of native T1 of 
1085 ms differentiated viable from non-viable segments with 
88% sensitivity and 88% specificity. Clustered ROC curve 
analysis showed that segmental T1 mapping had an AUC of 
0.8338 (95% CI 0.7002–1.00) to predict viability.
Mixed effects model with random intercept
Generalized linear mixed effect models, with the random 
intercept to assess the association between native T1 and via-
bility/TEI correcting for the class effect due to multiple seg-
ments from same person or same segment location. Presence 
of non viability was significantly associated with native T1 
(Chi square 307.02, p < 0.01), increasing it by 131.9 ± 6.3 ms 
(standard errors). TEI significantly affected T1 (Chi square 
388.9, p < 0.01), increasing it by 2.07 ± 0.1 ms (standard 
errors) for every percent increase in TE.
Acute MI
T1 mapping versus scar transmurality (TEI)
In patients with acute MI, the segmental T1 correlated sig-
nificantly with LGE TEI with R = 0.57, p < 0.001 Fig. 3a. 
The mean segmental T1 value for scar transmurality grade 
0 (no LGE) was 1054 ± 65 ms, LGE positive but viable (scar 
grade 1–3): 1135 ± 73 ms and LGE positive but non viable 
(scar grade 4): 1168 ± 71 ms. The mean segmental T1 in 
the three categories (no LGE, LGE positive but viable and 
LGE positive but non-viable) were significantly different on 
a pairwise comparison with Bonferroni correction (p < 0.01) 
Fig. 3b. The mean native T1 in the infarct core and remote 
myocardium were 1308 ± 71 ms and 1054 ± 65 ms respec-
tively Table 2.
When grouping the segments into coronary artery ter-
ritories, the correlation between native T1 and LGE TEI for 
RCA, LCx and LAD territories were R = 0.66, 0.57, 0.57 
respectively(p < 0.001) Fig. 3c.
T1 mapping as a marker of transmurality of infarction
ROC analysis of segmental native T1 in acute MI against 
gold standard LGE viability(> 75%TEI) showed good diag-
nostic accuracy AUC-0.83(CI 0.78–0.88, p < 0.001) Fig. 3d. 
A T1 threshold of 1110 ms most optimally differentiated 
viable from non-viable segments with 79% sensitivity and 
79% specificity. Clustered ROC curve analysis showed that 
segmental T1 mapping had an AUC of 0.8338 (95% CI 
0.7587–0.9088) to predict viability.
Mixed effects model with random intercept
Presence of non viability was significantly associated with 
native T1 (Chi square 145.4, p < 0.01), increasing it by 
100.1 ± 7.7 ms (standard errors). TEI significantly affected 
native T1 (Chi square 206.1, p = < 0.01), increasing it by 
1.5 ± 0.1 ms (standard errors) for every percent increase in 
TEI.
Table 2  Mean native T1(in ms) in the LGE negative segments, LGE positive but viable segments, LGE positive non-viable segments, Infarct 
core and Remote myocardium
Category LGE negative 
segments




Infarct core Remote myocardium
Chronic MI Mean T1 (ms) ± SD 1031 ± 31 1103 ± 57 1206 ± 118 1171 ± 76 1005 ± 19
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T2w STIR area at risk (oedematous area) in acute MI
All the acute MI scans showed evidence of myocardial 
oedema in the infarct related artery territory. The area at 
risk (total area of oedema) in the acute MI was 31 ± 12% of 
the total LV.
Global native T1
Global native T1 in normal versus affected
Global native T1 in normal healthy volunteers was compared 
with all patients with previous MI (acute and chronic). The 
mean global T1 in normal volunteers was 1028 ± 28 ms, 
which was significantly lower than patients with previ-
ous MI 1070 ± 36 ms, p < 0.0001. The global native T1 in 
patients with acute MI was 1082 ± 34 ms (p < 0.0001 vs nor-
mal volunteer), whereas for chronic MI it was 1058 ± 34 ms 
(p = 0.002 vs normal volunteer) Fig. 4.
Fig. 3  a Scatter plot: Acute MI cohort showing native T1 value ver-
sus the LGE TEI, b bar diagram with error bar(SD): Acute MI cohort 
showing segmental native T1 value in LGE negative, LGE positive 
with viability and LGE segments with non-viability c scatter plot: 
Correlation betw en segmental T1 and Transmural extent of Infarct—
as per coronary artery territory in acute MI d ROC curve: Acute MI 
cohort comparing segmental native T1 versus LGE viability
Fig. 4  Boxplot showing the global native T1 in acute MI cohort, 
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Global native T1 versus Infarct size
Global native T1 was compared with the infarct size. For 
the total cohort (n = 60) it showed a good positive correla-
tion r = 0.575, p < 0.001. Subgroup analysis: the correlation 
was found to be excellent in chronic MI r = 0.717, p < 0.001 
whereas for acute MI it was weakly significant r = 0.365, 
p = 0.048 (Fig. 5a).
Global native T1 versus LV EF
Global native T1 was compared with the left ventricular 
ejection fraction. For the total cohort (n = 60) it showed a 
significant inverse correlation r = − 0.445, p < 0.001. Sub-
group analysis: the correlation was found to be statistically 
significant in chronic MI r = − 0.596, p < 0.001 but not in 
acute MI r = − 0.291, p = 0.118 Fig. 5b.
T1 mapping versus wall motion score versus wall 
thickness for the assessment of viability
Segmental native T1 was compared with segmental wall 
thickness and segmental wall motion score against gold 
standard LGE viability. ROC analysis of the 960 segments 
for viability assessment showed the highest diagnostic 
accuracy of T1 mapping (AUC − 0.9, 95%CI 0.87–0.93, 
p < 0.0001) when compared to wall motion score (AUC 
0.837, p < 0.0001, 95%CI 0.8–0.875), and segmental wall 
thickness (AUC 0.453, p = 0.07, 95%CI 0.401–0.505) Fig. 6.
Fig. 5  a Scatter plot showing the correlation between global T1 and infarct size, b Scatter plot showing the correlation between global T1 and 
LV ejection fraction
Fig. 6  ROC curve: comparing segmental native T1, segmental wall 
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• Among	 the	 conventional	 risk	 factors	 and	 CMR	 characteristics,	 ST-segment	
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